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Abstract 
A 16-kDa proteolipid, mediatophore, in Torpedo electric organs mediates 
Ca2+-dependent acetylcholine release. Mediatophore is identical to the 
pore-forming stalk c-subunit of the V0 sector of vacuolar proton ATPase 
(ATP6V0C). The function of ATP6V0C in the mammalian central nervous 
system is not clear. Here, we report transfection of adeno-associated viral 
vectors harboring rat ATP6V0C into the mouse substantia nigra, in which 
high potassium stimulation increased overflow of endogenous dopamine 
(DA) measured in the striatum by in vivo microdialysis. Next, in the 
striatum of 6-hydroxydopamine-lesioned mice, a model of Parkinson’s 
disease (PD), human tyrosine hydroxylase, aromatic L-amino-acid 
decarboxylase and guanosine triphosphate cyclohydrolase 1, together with 
or without ATP6V0C, were expressed in the caudoputamen for rescue. 
Motor performance on the accelerating rotarod test and 
amphetamine-induced ipsilateral rotation were improved in the rescued 
mice coexpressing ATP6V0C. [3H]DA, taken up into cultured N18 
neuronal tumor cells transformed to express ATP6V0C, was released by 
potassium stimulation. These results indicated that ATP6V0C mediates DA 
release from nerve terminals in the striatum of DA neurons of normal mice 
and from gene-transferred striatal cells of parkinonian mice. The results 
suggested that ATP6V0C may be useful as a rescue molecule in addition to 
DA-synthetic enzymes in the gene therapy of PD. 
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1. Introduction 
 In both rodent and non-human primate models of Parkinson’s 
disease (PD), viral vector-mediated gene delivery of one or three dopamine 
(DA)-synthesizing enzyme(s) into the striatum has been shown to 
ameliorate motor symptoms with efficient transduction of putaminal 
neurons (Shen et al., 2000; Muramatsu et al., 2002; Sun et al., 2004: Li et 
al., 2006; Bankiewicz et al., 2006; Svendsen, 2007; Fiandaca et al., 2008). 
In addition to tyrosine hydroxylase (TH) and aromatic L-amino-acid 
decarboxylase (AADC), GTP cyclohydrolase I (GCH) is necessary for 
efficient DA production (Shen et al., 2000; Muramatsu et al., 2002; Sun et 
al., 2004; Iancu et al., 2005). Using adeno-associated virus (AAV) vectors, 
two phase 1 clinical investigations of gene therapy for PD are underway 
based on these animal studies (Christine et al., 2009; Muramatsu et al., 
2010b). In these protocols, gene transfer of AADC into the human putamen 
is combined with oral administration of L-3,4-dihydroxyphenylalanine 
(L-dopa). Expression of AADC would convert L-dopa to DA in the 
putamen. However, the mechanism of DA release from transduced cells 
remains to be elucidated. 
 Nerve terminals from dopaminergic neurons of the substantia nigra 
(SN) are selectively degraded and mostly lost in the putamen of PD 
(Nagatsu and Ichinose, 1999). This indicates that DA synthesized by 
extrinsic enzymes could be released from the soma of transduced neurons 
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or astrocytes, in which the fusion of exocytotic vesicles and vesicular 
secretory apparatus are not completely identical to those in the nerve 
terminals (Montana et al., 2006). Therefore, we postulated another 
mechanism in which a complex of proteolipid channels in SNARE fusion 
as described in yeast and Drosophila (Peters et al., 2001; Almers, 2001; 
Hiesinger et al., 2005) is effective in DA secretion from gene 
therapeutically DA-expressing cells in the striatum.  
 To assess the validity of this mechanism, we used mediatophore, a 
16-kDa proteolipid originally found in the presynaptic membrane of the 
Torpedo electric organ (Israel et al., 1986 and 1991). Mediatophore was 
later shown to be an ortholog of mammalian C subunit in the V0 
transmembrane sector of vacuolar proton ATPase (ATP6V0C; Nezu et al., 
1992; Dunant & Israel, 2000; Hinton et al., 2009; Ediger et al., 2009; Di 
Giovanni et al., 2010; El Far and Seagar, 2011). ATP6V0C forms a 
proteinaceous pore (Zimmerberg, 2001; Dunant & Israel, 2000; Morel et 
al., 2001;Drory et al., 2004; Inoue and Forgac, 2005; Drory and Nelson, 
2006; Zhang et al., 2006) and mediates the Ca2+-dependent and fast release 
of acetylcholine (ACh; Falk-Vairant et al., 1996a and b; Dunant & Israel, 
2000; Malo & Israel, 2003; Dunant et al., 2009). In addition, the direct 
interaction between ATP6V0C and vesicular-soluble 
N-ethylmaleimide-sensitive factor attachment protein receptors 
(v-SNARE) synaptobrevin and its effects on modulation of ACh release 
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have been reported (Di Giovanni et al., 2010; El Far and Seagar, 2011). 
However, the roles of ATP6V0C in the central nervous system on DA 
secretion have not yet been reported. 
 Here, we examined the effects of ATP6V0C on DA release in the 
mouse striatum after transfection with AAV harboring ATP6V0C and 
DA-synthesizing enzymes (Muramatsu et al., 2002). We examined the 
effects of ATP6V0C on motor behavior in a unilateral 6-hydroxydopamine 
(6-OHDA)-lesioned mouse model of PD. Furthermore, we examined DA 
release more directly using cultured neuronal cells. NG108-15 
neuroblastoma × glioma hybrid (Nirenberg et al., 1983a and b; Higashida 
et al., 1986) and C6 glioma cells possess ATP6V0C, while no such protein 
was detected in N18 neuroblastoma clonal cells (Amano et al., 1972; 
Falk-Vairant et al., 1996a and b). It has been reported that ACh is not 
synthesized in N18 cells (Amano et al., 1972) and that ACh is not released 
from transformed N18 cells to express choline acetyltransferase (Zhong et 
al., 1995a and b) but released from N18 cells forced to express ATP6V0C 
(Falk-Vairant et al., 1996a and b). Therefore, we examined whether 
[3H]DA is released from NG108-15 hybrid cells with endogenous 
ATP6V0C or N18 neuroblastoma cells transfected with ATP6V0C.  
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2. Experimental procedure 
 
2.1. Animals 
 Wild-type adult male mice of the ICR strain were kept in the 
animal center under standard conditions (24°C; 12-h light/dark cycle, lights 
on at 08:00) and received food and water ad libitum. The experiments were 
carried out in accordance with the Guidelines for the Care and Use of 
Laboratory Animals of Kanazawa University.  
 
2.2. 6-Hydroxydopamine-lesioned mice 
 Mice were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) 
and placed in a stereotaxic apparatus. A small hole was made in the skull 
using a dental drill, and a 25-gauge stainless steel injection needle was 
inserted into the right striatum. A 2-µL aliquot of 6-OHDA dissolved in 
0.02% ascorbic acid in saline was injected into the substantia nigra over a 
period of 2 min at a speed of 1 µL/min (total injected amount: 28 µg of 
6-OHDA). The needle was left in place for an additional 3 min and then 
withdrawn slowly. Control animals received PBS into the substantia nigra 
according to the same procedure.  
 7 
 To validate that 6-OHDA effectively induced DA depletion, 
d-amphetamine-induced rotations were quantified at 4 weeks after 
microinjection of 6-OHDA. To measure rotational behavior, each mouse 
was placed in the center of an open field (a circle with a radius of 30 cm), 
and the number of complete turns was recorded during each 5-min period 
for 60 min. Mice were allowed 15 min to habituate to the open field before 
administration of d-amphetamine (3 mg/kg, i.p.). Only those animals 
exhibiting ≥ 7 ipsilateral rotations/min in a 60-min period at 4 weeks after 
6-OHDA injection were included in further analysis.  
 
2.3. Production and use of AVV 
 For generation of AAV vectors, we used vector plasmids 
containing an expression cassette, in which a human cytomegalovirus 
immediate-early promoter (CMV promoter) was followed by the first 
intron of the human growth hormone gene, the cDNA of TH, AADC, GCH, 
forward or reverse form ATP6V0C (Nezu et al., 1992), ATP6V0C-GFP, 
woodchuck hepatitis virus posttranscriptional regulatory element and 
simian virus 40 polyadenylation signal sequence between the inverted 
terminal repeats (ITR) of the AAV-2 genome. We used two helper 
plasmids, pAAV-RC and pHelper, harboring the AAV rep and cap genes, 
and the E2A, E4, and VA1 genes of the adenovirus genome, respectively 
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(Agilent Technologies, Santa Clara, CA). HEK293 cells were cotransfected 
with the vector plasmid, pAAV-RC and pHelper using the calcium 
phosphate coprecipitation method. AAV particles were then harvested and 
purified by two sequential continuous iodoxale ultracentrifugations. The 
vector titer was determined by quantitative PCR of DNase-I-treated vector 
stocks. We routinely obtained 1012 – 1013 vector genome copies (vg). 
 
2.4. Infection with AAV 
 AAV vector expressing either forward or reverse form of 
ATP6V0C was injected stereotaxically into the bilateral caudoputamen 
(CPU) of intact mice. Phosphate buffer solution (PBS) was injected in the 
CPU of control mice. In other experiments, mixtures of three separate 
AAV vectors expressing TH, AADC, and GCH, or in addition of two types 
of ATP6V0C, were injected stereotaxically into the unilateral CPU of 
hemiparkisonian mice six weeks after the 6-OHDA treatment.  
 
2.5. In vivo microdialysis  
 Wild-type ICR mice (11 – 13 weeks old; n = 6 – 8) were 
anesthetized with sodium pentobarbital (50 mg/kg, i.p.), and a guide 
cannula (AG-4; Eicom Corp., Kyoto, Japan) was implanted into the CPU 
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(+2.0 mm anterior, –0.5 mm lateral from the bregma, –2.0 mm ventral from 
the skull) according to the mouse brain atlas. On recovery from surgery, a 
dialysis probe (A-I-4-01; membrane length 1 mm; Eicom Corp.) was 
inserted through the guide cannula, and perfused with artificial 
cerebrospinal fluid (aCSF; 147 mmol/L NaCl, 4 mmol/L KCl, and 2.3 
mmol/L CaCl2) at a flow rate of 1.0 µL/min. The outflow fractions were 
collected every 10 min. After collection of baseline fractions, high 
potassium-containing aCSF (50 mM; isomolar replacement of NaCl with 
KCl) was perfused for 20 min through the dialysis probe. DA levels in the 
dialysates were analyzed using an HPLC system (HTEC-500; Eicom 
Corp.) equipped with an electrochemical detector, as described previously 
(Jin et al., 2007). The probe recoveries of DA were approximately 25%. 
 
2.6. Immunostaining of brain sections  
 Brains were perfused with 4% paraformaldehyde, soaked in 30% 
sucrose, and dissected into coronal sections (30 µm). TH monoclonal 
antibody (1:800 or 1:8000; DiaSorin, Stillwater, MN) was used. 
Appropriate fluorescence-tagged (Invitrogen, Carlsbad, CA) or biotinylated 
(Vector Laboratories, Burlingame, CA) secondary antibodies were used for 
visualization. Immunoreactivity was assessed under microscopy (Olympus, 
Tokyo, Japan).  
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2.7. Motor behavior test with the rotating rod 
 The degrees of motor impairment were evaluated by measuring 
latency until falling from an accelerating rotating rod (diameter, 3 cm), the 
speed of which was slowly increased from 3 to 30 rpm within 5 min 
(Rotarod Apparatus Model MK-670; Muromachi Kikai, Tokyo, Japan). For 
3 days before the 6-OH-injection to produce the nigra-caudate lesion, all 
mice were habituated to the rotarod test to minimize novelty stress and to 
achieve similar performance in the task. The time until falling off the 
rotating rod was measured. 
 
2.8. Amphetamine-induced rotation test 
 d-amphetamine-induced rotation was used to estimate the extent of 
DA release in the striatum on three successive days three weeks after 
vector injection. d-amphetamine (3 mg/kg) was administrated 
intraperitoneally to the mice that had been treated with AAV vectors 
expressing TH, AADC, GCH, forward or reverse form ATP6V0C in the 
lesion side of the striatum. The criterion for ipsilateral abnormal rotation 
was more than 10 full turns per minute over 30 minutes on each 
examination day, as described previously (Imamura et al., 2003). 
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2.8. Experiments on release of [3H]DA  
 N18 neuroblastoma and NG108-15 hybrid cells (Amano et al., 
1972; Nirenberg et al., 1983a; Suzuki et al., 1983) were grown for 6 days 
in the presence of 1 mM dibutyryl cyclic AMP on 60-mm 
polyornithine-coated dishes (Higashida et al., 1986). The experiment was 
performed in the presence of 10 µM pargyline, as described previously 
(Furuya et al., 1985). Cultures were incubated with PBS for 30 min at 37°C. 
After rinsing, they were incubated with 1 µM [3H] DA (1.11 TTBq/mmol; 
PerkinElmer, Wellesley, MA) for 1 h. They were then washed 3 times with 
PBS and incubated for successive 4-min periods in changes of PBS. High 
K+ solution was prepared by iso-osmolar substitution of KCl (to 80 mM) 
for NaCl. CaCl 2 (1.8 mM) was omitted and 0.1 mM EGTA was added in 
some incubations. After the end of each 4-min period, the incubation 
medium was removed and fresh medium was added to the cultures. The 
incubation medium was passed through a 3 × 1 cm Sephadex G-10 
column and eluted with 6 mL of H 2O followed by 3.1 mL of 0.5 M formic 
acid. The radioactivity in each fraction was estimated by liquid scintillation 
spectrometry. 
 
2.9. Statistical analysis  
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 All results are expressed as means ± SEM. One-tailed t test and 
one-way ANOVA combined with the Bonferroni test were used to analyze 
data with unequal variance between groups using the Stata data analysis 
and statistical software (StataCorp, College Station, TX). In all analyses, P 






3.1. Effects of ATP6V0C on DA release in intact mice 
 To identify functional roles of ATP6V0C in the central nervous 
system, we expressed ATP6V0C in the mouse brain using the constructed 
AAV vectorsharboring cDNAs of rat ATP6V0C, its reverse form, and 
ATP6V0C-GFP. Infection of these viruses in the substantia nigra of the 
intact mouse brain revealed ATP6V0C-GFP expression in both 
TH-positive neurons and TH-negative cells, probably astrocytes (Fig. 1a – 
c). 
 Based on this information, DA overflow from the synaptic cleft in 
the striatum of mice treated with AAV vectors in the substantia nigra was 
measured by the in vivo microdialysis method. DA release was 
significantly higher in the mice infected with AAV-ATP6V0C under both 
resting (at 5 mM of extracellular potassium concentration) and depolarizing 
(50 mM) conditions (Fig. 2; n = 6 – 8, one-way ANOVA, F5,49 = 
19.96 *P < 0.05 or **P < 0.001). Viral infection with reverse 
direction of ATP6V0C had no or little effect on DA release, comparable to 
the control (sham-operated with PBS injection) mice. We used reverse 
ATP6V0C as an additional control, instead of controls with vector alone, in 
the subsequent experiments. 
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3.2. Behaviors in hemiparkinsonian mice with or without ATP6V0C 
 Next, we examined the effects of ATP6V0C on recovery from 
motor impairment elicited in a unilateral 6-OHDA-lesioned mouse model 
of PD, in which AAV vectors of two types of ATP6V0C in addition to DA 
synthetic enzymes, TH, AADC, and GCH were infected on the striatum. 
Motor performance of 6-OHDA-treated mice was examined based on the 
latency to fall from the rotarod. 6-OHDA mice treated with 3 
DA-synthesizing enzymes and ATP6V0C showed significantly improved 
performance on the rotarod compared with control lesioned mice treated 
with PBS alone (Fig. 3). The mean recovery by enzymes, enzymes with 
reversed ATP6V0C, and enzymes with ATP6V0C was to 43, 45 and 77% 
levels from 19% of the ability of the intact mice, respectively (*, **, ***P 
< 0.05, 0.01 and 0.001, respectively; F4,20 = 40.42, P < 0.001; n = 5). 
 As d-amphetamine-induced rotation shows the highest 
predictability of nigral TH cell loss (Iancu et al., 2005; Fleckenstein et al., 
2007), we next examined the effects of amphetamine. Three weeks after 
lesion generation, mice exhibited ipsilateral turning induced by 
intraperitoneal injection of 3 µg/kg of d-amphetamine (Fig. 4). The number 
of rotations was significantly decreased in mice transfected with 3 enzymes 
(14.9 ± 1.2 rotations/3 min), 3 enzymes plus reverse ATP6V0C (13.9 ± 
4.3), and 3 enzymes plus ATP6V0C (4.0 ± 1.0), compared with control 
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mice injected with PBS (31.7 ± 2.0) (one-way ANOVA, F3,12 = 55.44, P 
<  0.001. *P < 0.01, **P < 0.002, and ***P < 0.001, respectively 
(n = 4)). In sham-operated mice, no rotation was induced by 
amphetamine (n = 4).  
 
3.3. [3H]DA release from N18 cells expressing ATP6V0C or NG108-15 
cells  
 Finally, we tested the hypothesis of [3H]DA release through 
ATP6V0C in vitro. We cultured N18 neuroblastoma cells, which have no 
endogenous ATP6V0C (Falk-Vairant et al., 1996a and b) and no ACh 
release capacity (Zhong et al., 1995a and b; Falk-Variant et al., 1996a and 
b). The cells were preloaded for 1 h in 1 µM [3H]DA in the presence of 
pargyline (Furuya et al., 1985). The release of [3H]DA and its metabolites 
were measured. As expected, an increase in K+ concentration in the 
perfusion medium to 80 mM (at 20 and 24 min) resulted in no detectable 
increase in release, compared from concentrations in the other period 
(one-way ANOVA, F7,16 = 2.89,  P = 0.037; Fig. 5a). However, when 
identical experiments were performed in N18 cells transfected with 
ATP6V0C, [3H]DA was released due to high-potassium stimulation in a 
Ca2+-dependent manner (F8,27 = 18.61,  P < 0.001 (Fig. 5b)). 
 NG108-15 neuroblastoma × glioma hybrid cultured cells with 
endogenous ATP6V0C (Falk-Vairant et al., 1996a and b) were preloaded 
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with [3H]DA. An increase in the K+ concentration resulted in a 1.8 ± 
0.5-fold (n = 3) increase in release of radioactivity. Repeating the K+ 





 The results of the present study demonstrated for the first time that 
DA could be released from nigrostriatal cells overexpressing ATP6V0C of 
mice and from cultured neuronal cells endogenously or exogenously 
expressing ATP6V0C in a Ca2+-dependent manner. The precise mechanism 
underlying the Ca2+-dependent DA release is not yet clear. However, as 
ATP6V0C binds to syntaxin in SNARE complexes (Shiff et al., 1996) or 
shows direct interaction with v-SNARE synaptobrevin (Di Giovanni et al., 
2010; El Far and Seagar, 2011), ATP6V0C may cooperate with SNARE 
proteins and vesicles for release at the late stage of fusion. Our finding of 
DA release through proteolipid fusion pores suggested that the vesicles 
may be recycled without undergoing full fusion with the plasma membrane, 
i.e., the “kiss-and-run” process (Ales et al., 1999; Fesce and Meldolesi, 
1999; Valtorta et al., 2001; Rizo and Rosenmund, 2008). 
PD is a common neurodegenerative disorder in the elderly (Samili 
et al., 2004). Characteristic motor symptoms, which include resting tremor, 
muscular rigidity, and bradykinesia, are caused by a severe decrease in the 
DA content of the striatum secondary to progressive loss of nigrostriatal 
DA neurons (Santini et al., 2009). Replacement of DA in the striatum is 
important for functional recovery regardless of damage sustained by the 
nigrostriatal DA pathway. With recombinant AAV vectors, gene therapy is 
becoming a feasible therapeutic option for PD (Lees et al., 2009; 
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Muramatsu et al., 2010a). 
Efficient and long-term expression of genes for DA-synthesizing 
enzymes in the striatum restored local DA production and allowed 
behavioral recovery in animal models of PD (Muramatsu et al., 2002). 
Baseline striatal dopaminergic neurotransmission in the normal striatum is 
maintained by tonic synaptic and non-synaptic DA release, which is largely 
independent of changes in neuronal impulse flow in the nigrostriatal 
pathway. As in previous studies (Shen et al., 2000; Muramatsu et al., 2002; 
Bankiewicz et al., 2006), the majority of transduced cells were neurons. As 
most of the striatal neurons express DA receptors that are internalized in 
response to alterations in dopaminergic tone (Dumartin et al., 1998; Muriel 
et al., 1999), DA produced in striatal neurons may bind to cytoplasmic DA 
receptors. However, we previously detected efficient baseline and 
L-dopa-induced DA release in the AAV-TH/-AADC/-GCH-injected 
putamen by microdialysis (Muramatsu et al., 2002), suggesting that the DA 
synthesized by these extrinsic enzymes was released by a non-synaptic 
mechanism or from non-neuronal elements such as astroglial cells. To our 
knowledge, these results represent the first insight into the possible 
involvement of ATP6V0C in these phenomena. 
We demonstrated that ATP6V0C expression in the striatum 
increased endogenous DA release due to depolarization in the intact brain 
(Fig. 2).  However, we did not measure DA release in the 6-OHDA- 
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lesioned brain with the same paradigm. Therefore, it will be interesting if 
we can show an evidence of recovery at the DA release level using in vivo 
microdialysis for ameliorating behavioral impairments with 3 enzymes 
and/or ATP6V0C. Such experiments currently underwent. 
 The results of the present study indicated that DA is similarly 
released from N18 neuroblastoma cells expressing ATP6V0C and 
NG108-15 cells with endogenous ATP6V0C and dense core vesicles 
(Furuya et al., 1985), although it is not yet clear what types of 
neurotransmitters are packed into such organelles. NG108-15 cells 
synthesize and uptake serotonin from the extracellular medium when 
loaded with [3H]serotonin, and released [3H]serotonin in a Ca2+-dependent 
manner (Suzuki et al., 1983; Furuya et al., 1985). Therefore, it is possible 
that serotonin and DA share the ATP6V0C-dependent mechanism for 
release from NG108-15 cells. 
 In conclusion, we observed better improvement in movement 
impairment in mice expressing 4 proteins (TH, AADC, GCH, and 
ATP6V0C) than 3 (TH, AADC, and GCH). This concept of additional 
effects with ATP6V0C suggested that ATP6V0C may be useful in future 
gene therapy for PD, in addition to TH, AADC, GCH, and the DA 
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Fig. 1. A sample with ATP6V0C-GFP expression in cells in the substantia 
nigra of mice at two weeks after transfection with AAV. a, Tyrosine 
hydroxylase (red) in dopaminergic neurons. b, ATP6V0C (green) 
expressed in cells. c, Merge of the two, showing expression in a 
dopaminergic neuron and non-dopaminergic cells (arrowheads). Bars 20 
µm.  
                                                                                                                                                                                                                                                                                          
Fig. 2. Extracellular striatal DA levels measured by in vivo microdialysis in 
wild-type mice at two weeks after transfection with PBS or reverse 
ATP6V0C (rev) and ATP6V0C (V0C) genes. Dialysates were collected by 
perfusion with artificial CSF containing 5 mM and 50 mM K. n = 6 – 
8, *P < 0.01, **P < 0.001. 
 
Fig. 3. Rotarod performance tested in the 6-OHDA mouse model of PD by 
treatment with AAV-TH/-AADC/-GCH (Enz) with or without ATP6V0C 
or reverse ATP6V0C. Mice with relatively complete lesions were used for 
gene transfer; these mice received the 3 or 4 gene vectors, or PBS alone. 
The mice were tested starting 3 weeks after gene transfer. n = 5 
lesion-positive mice. *, **, ***P < 0.05, 0.01, and 0.001, respectively. 
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Fig. 4. Amphetamine-induced rotations/3 minutes in mice prepared 
similarly to those described in Fig. 3. Each bar indicates the net mean turns 
(mean ± SEM) for each test, in the ipsilateral direction over 90 min after 
injection of d-amphetamine. n = 3. *P < 0.01, **P < 0.002, or ***P 
< 0.001. 
 
Fig. 5. Release of [3H]DA. Three and four N18 neuroblastoma cells 
transfected with (b) or without (a) ATP6V0C were preloaded with 1 µM 
[3H]DA for 1 h. The cells were incubated for successive 4-min periods in 
the indicated solutions (normal PBS containing 1.8 mM Ca2+ with or 
without calcimycin, PBS excluding Ca2+ and including 0.1 mM EGTA, or 
80 mM K-PBS). Bars represent SEM. N.s., not significant bewtten two bins 
during high potassium stimulation and other others in (a). *, **P < 0.01 and 
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